Life Science Partners (LSP), an Amsterdam-based investment firm that provides finance for life sciences and health care companies, announced that it has raised over €1B for its flagship fund LSP 7.
With the LSP 7 fund, the Dutch firm plans to invest in 15 to 20 companies developing new drug therapies and medical technologies. To date, LSP has already invested in four companies. There are:
- Evommune – dermatology, and immunology
- Egle Therapeutics – oncology and autoimmune diseases
- Hotspot – autoimmune diseases, rare diseases, and oncology
- Undisclosed radiotherapy company
In November 2021, LSP announced that it had raised €850M for LSP 7 and is intending to join forces with EQT. The transaction with EQT is expected to close in Q1 2022. Post that, LSP will be renamed EQT Life Sciences.
‘’Just one day after the announcement of our partnership with EQT, a large investor decided to pursue a €150M investment in LSP 7, bringing the fund straight to the maximum size (hard cap) of €1B. This investment immediately validates a key rationale for joining EQT: with EQT, we expect that we will be able to raise large funds much faster, serving the life sciences in Europe even better than before,’’ says René Kuijten, managing partner of LSP and incoming head of EQT Life Sciences.
LSP: What you need to know
LSP is an Amsterdam-based investment firm providing financing for life sciences and health care companies. LSP’s management has raised over €3.1B and supported over 150 companies, including signature deals such as argenx, Crucell and Neuravi.
With offices in Amsterdam, Munich and Boston, LSP currently can invest through several strategies with different investment scopes and a dedicated team.
LSP is an active contributor to the global life sciences industry and the European life science ecosystem by assuming roles as initiators, founders and board members in various private and public bodies, and organisations.
EQT: What you need to know
EQT is a purpose-driven global investment organisation with more than €73.4B in assets under management across 28 active funds.
EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately €9B and more than 175,000 employees.
